[ad_1]
On the morning of Sunday, December 13, the commissioner for the coronavirus emergency in Italy, Domenico Arcuri, presented during a press conference together with the architect Stefano Boeri the communication plan for the coronavirus vaccination campaign, which will be launched march in first weeks of next year. The symbol in the center of communication will be the primrose, a fairly common flower in Italy and one of the first to open at the end of the cold season. The idea, Boeri explained, is to offer a coordinated image of the entire campaign, using a symbol associated with the idea of recovery and return to life.
– Read also: Who was Arcuri before becoming Arcuri?
Boeri is one of the best known and most appreciated Italian architects and has provided his advice to the government free of charge. Together with the collaborators of his study, he proposed the guidelines that the institutions will follow to manage the communication campaign for vaccination. The corporate identity project includes logos, characters, illustrations and images that will be used to communicate the initiatives around the coronavirus vaccine.
The main symbol chosen is a primrose in a rather stylized form, according to Boeri easy to recognize and identify in urban contexts and in the media. It will be accompanied by the phrase: “Italy is reborn with a flower. 19 ”anti-Covid vaccine. The logo may be placed next to the symbol of the Republic in institutional communications.
In addition to the symbol, the project for the construction of the pavilions that will be located in various Italian cities was also presented, with information on vaccination and areas dedicated to the administration of vaccines.
They will be cylindrical structures with movable internal dividers, which can then be moved to organize the spaces differently according to needs. The roof will have solar panels to produce the electricity that the pavilion needs, while the main structure will be made of wood and can be dismantled and reassembled in different areas of the city.
The circular shape should favor an orderly flow of visitors and health personnel who will administer the vaccines.
The symbol of the vaccination campaign will be present on the sides and on the ceiling of each pavilion, so that it is easily recognizable.
However, during the presentation, Arcuri did not provide much information about how many pavilions will be built in Italy, nor how its activity will be coordinated with that of clinics, hospitals and other facilities that will administer the vaccine. However, he confirmed that at full capacity the administration sites will be at least 1,500 in Italy, but also in this case without providing data on the methods and times of realization.
As Health Minister Roberto Speranza explained a few days ago in Parliament, the government plans to start vaccinations in mid-January and begin with health personnel and guests in nursing homes. This first phase dedicated to those most at risk should affect approximately 1.8 million people, but it is not clear whether sufficient doses will be available immediately to proceed quickly.
Arcuri said he expects vaccinations to begin on January 15 in a coordinated manner across the European Union, which in recent months has been in charge of reserving vaccines that are being tested and approved on behalf of member states. The beginning must be accompanied by a symbolic day with initiatives shared by the different EU countries to communicate the importance of vaccination. However, many details are still being defined, as are the agreements at the European level.
In the first phase of vaccinations, the announced wards will be limited in number, precisely because the vaccines will be administered to a specific segment of the population. Subsequently, with the availability of a greater number of doses, more rooms should be installed and an online reservation system should be launched, about which there is still no clear information.
To date, in the European Union, the use of any coronavirus vaccine in the population has not yet been authorized. European authorities are expected to authorize the Pfizer-BioNTech vaccine by the end of the year and then proceed with the authorization of the similar Moderna vaccine early next year. Meanwhile, other manufacturers are finishing testing their solutions, which should then be licensed later in the year.
– Read also: The United States has licensed the Pfizer-BioNTech vaccine
[ad_2]
